摘要
目的观察小细胞肺癌(SCLC)患者IP[伊立替康(CPT-11)65 mg·m-2,第1、8天,静脉滴注,顺铂(40 mg·m-2)第2～3天]方案化疗前后CEA、CA125、NSE的水平变化,以此观察疗效,并探讨该几项指标在小细胞肺癌疗效评价方面的临床意义。方法收集30例治疗前CEA、CA125、NSE升高小细胞肺癌患者,分别于化疗前及治疗2周期后,检测血清CEA、CA125及NSE水平。用CMIA法检测CEA、CA125;用ECLI法检测NSE。结果小细胞肺癌患者CEA、CA125、NSE水平治疗2周期后均较治疗前下降,CEA、CA125下降有统计学意义(P<0.05);NSE下降有统计学意义(P<0.01)。结论小细胞肺癌患者在IP方案治疗后较治疗前CEA、CA125、NSE降低,可以预测IP方案治疗小细胞肺癌的疗效。
Objective To observe changes of serum NSE, CEA and CA125 in patients of small cell lung cancer before and after with IP （ irinotecan, CPT-11 65 mg . m^ -2, days 1,8, intravenous infusion , cisplatin, 40 mg . m^ -2, days 2,3 ） chemotherapy. According to the observation,we investigated the clinical significance of these indicators in the evaluation of small cell lung cancer. Methods Thirty small cell lung cancer patients serum CEA, CA125, NSE with increased before chemotherapy were selected,whose serum CEA, CA125 and NSE levels before chemotherapy and after 2 cycles of treatment were detected respectively. CEA, CA125 were detected with the CMIA method, NSE with ECLI method. Results CEA, CA125, NSE level decreased after 2 cycles of treatment compared with before treat- ment. CEA, CA125 declines were statistically significant（P 〈0.05） ,so was NSE decline （P〈0.01）. Conclusions CEA, CA125, NSE decrease in small cell lung cancer patients after treatment with the IP program compared with before treatment, and can predict the therapeutic effect of IP chemotherapy on small cell lung cancer.
出处
《安徽医药》
CAS
2013年第11期1901-1902,共2页
Anhui Medical and Pharmaceutical Journal
关键词
小细胞肺癌
化学疗法
癌坯抗原
神经元特异性烯醇化酶
small cell lung cancer
chemotherapy
carcinoma embryonic antigen
neuron specific enolase
